Travere Therapeutics reported third-quarter 2025 earnings, highlighting revenue of US$164.86 million and net income of US$25.71 million, a sharp turnaround from the net loss a year earlier, with ...

Travere Therapeutics (TVTX) delivered a quarterly update that caught investors’ attention, as the company posted substantial revenue growth and turned a profit in Q3 2025. The results reflected strong ...

Discover key Q3 2025 earnings insights for Travere Therapeutics, including FILSPARI sales growth, FDA milestones, and outlook for rare kidney ...

Investing.com -- Travere Therapeutics, Inc. (NASDAQ:TVTX) reported third-quarter earnings that significantly exceeded analyst expectations, driven by robust sales growth of its kidney disease ...

Travere Therapeutics, Inc. (($TVTX)) has held its Q3 earnings call. Read on for the main highlights of the call. Travere Therapeutics, Inc.

The update now reduces the frequency of liver function monitoring to every 3 months from the onset of treatment. The Food and Drug Administration (FDA) has updated the risk evaluation and mitigation ...

Chugai is paying JP 15 billion ($98 million) upfront for Tokyo-based Renalys, with another JPY 16 billion on the table if its ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved updated Risk Evaluation and Mitigation Strategy (REMS) labeling for Travere Therapeutics, Inc.’s (NASDAQ:TVTX) Filspari (sparsentan), ...

Travere Therapeutics (TVTX) is scheduled to announce Q3 earnings results on Thursday, October 30th, after market close. The consensus EPS Estimate is -$0.09 (+8 ...

FILSPARI REMS: Due to the risk of hepatotoxicity, FILSPARI is available only through a restricted program called the FILSPARI REMS. Prescribers, patients, and pharmacies must be enrolled in the REMS ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American Society of Nephrology (ASN) Kidney Week ...

Shares of Travere Therapeutics rose after the company beat analysts' expectations in swinging to a third-quarter profit. The stock rose 14% to $33.67, and at one point touched a new 52-week high of ...